children.
Studies in animals indicate that the half-life (~) of SMC is longer (2-4 hr s) than that of other polypeptide hormones. This is believed to be due to the fact that SHe circulatea as part of a binding protein complex. Studies of the t~of SHC in IGnans have not been poasible due to t he scarcit y of purified SHC. We have estimated the t~of SHC in 11 children (SM , 3F) with GH deficiency. After 2 baaeline serum samples were obtained, each child received 5 doses of NPA hGH (0 .1 u/kg/dose) at 12 hr intervals. Serum samples were obtained at 24 hrs and 48 hrs of treatment and at 6 hr intervals after the last dose of hGH. Total SHC waa determined on acid-ethanol extracted samples using an RIA specific for SHe. The t~for SMC disappearance was 18.7~2.6 hrs (x~SEM). T~was not correlated with age, bone age or peak SHC. However, the time elapsed from the last hGH injection to SMC •~peak SHC waa correlated with bone age (r · 0.67, p 0.05) . In 8 children, growth velocities on hGH are availsble (8.2~2.5 cm/yr). Growth velocity wss not significantly correlated with bone age, peak SHe or t~. Conclusion : The t~of SHC in GH deficient children is considerably longer than the t~observed in small animals . The prolonged t~of SMC may partially explain the success of present GH treatment regimens in promoting skeletal growth.
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The purpose of this study was to compare the bioactivity (SM) and the binding activity (ILA) of s oma tome di n in 11 children with growth retardation and persistent GH secretion after cranial i r r adiation for medulloblastoma or head and ne ck tumors . Children aged 6-1 2 yr, first seen 16-54 mo after irradiation were investigated over periods of 6-36 mo. Each patient at invervals of 3 me or mor_ underwent 2 to 4 arginine-insulin tests with determinations of GR, SM by the porcine cartilage bioassay and ILA by RRA after plasma acid gel filtration . GH peak values were distributed from severe (5 ng/ml n -5 l, to partial (5-10 ng/ml n -13) or normal range (10 ng/ml n -7 l , All SM value s were low «0 .5 U/ml) . Mean ILA was lower than control but significantly higher than values obtained i n idiopathic hypopituitarism (IH) U/ml D.O. SOBEL*, J.P .GUTAI, B.S. RABIN*, B.J. MONDINO*. P. FIREMAN* . Universit y o f Pittsburgh School of Medicine, Pi t t s bur gh , PA. Cell mediated immunit y to pituitary extracts in hypopituitarism.
To obt a i n evidence of autoimmunity in children with idiopathic hypopituitarism, lymphocyte reactivit y to pituitary extract in 9 normal subjects and 3 children with idiopathic hypopituitarism was determined. Lymphocyte reactivity to thyroid extract wss also studied. Standard lymphoblastic transformation testing by thymidine incorporation was performed with crude human pitui tary extract at conc en t r a t i ons of 2.6 or 5.0 ug protein/ml & 26 or 50 Ug/ ml. For each set of replicate wells, the arithmetic mean of the square root counts per minute (~ICPH) was calculated. Thymidine incorporation was r ecorded as the difference of the test counts from the control (~~.~~to 2.5/5 .0 ug/ml in 9 normal subjects was -6.0(SO+ 6 .9). The~~to 26/50 Ug/ml extract was 0.66(S0+8.2) . One chi ld had~~3 4 to the higher extract concentration which was >95% tolerance l~its of normal subjects, 6 months later the~~40 to the lower extract concentration (>95% confidence limit s ). Thi s child had no significant~1ePR to thyroid extract. He has alopecia dystrophic nails and T and B cell dysfunction.~~to pituitary extract to two other children were within normal limits. In conclusion we describe an invitro test to detect cellular hypersensitivity to pituitary extract f or patients with hypopituitarism. We report 1 of 3 children tested with persistent lymphoc yte reactivity which appears to be organ specific . Clinical and laboratory presentation s ugges ts an autoimmune basis of h i s disease .
N. STEBBI NG, J.T. FENNO* and M. SANDA* Gene n t ec h , Inc. , So. San Franc i s c o , Calif orn ia 94080 U. S .A. Efficacy and pharmac okinetics o f recombinant DNA derived human growth hormone in rats and monkeys.
Pr oduction of human gr o~th ho rmone by bact eria harbor ing a plasmid gene increas es the pot ent ial ava ilab il it y of the hormone for human c li n i c a l u se. The ef f i ca c y o f thi s material has been determined by growth promot ing e f f ects i n rats and cl ini ca l chem istry parameter s i n ra ts and monk eys. Compar i s on o f the pharmacokinetic s of t he horm one admini st e red intramuscul arly or sub-cutaneously indi cates that essent ially similar effects are achieved. Other b i ochemi cal properties also indicat e t ha t the s ub-c u t a neo us r oute is not associated with po tent i al a dve r s e effects, supporting us e of t he material for a va ri e ty of cl ini c a l indications.
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Stunted growth due to peripheral resistance to sOlllltomedin, a new syndrom. Up to now small stature with high plasma-hGi is known only as Laron-t;ype dwarfism, caused by insufficient response of somatomedin (SH)-production to hGi. Recently we observed a dwarf with constantly elevated levels of hGi and of SH as well. Methods : hGi ace, to Schonberg (1972) , SH ace. to van den Brande &Caju (1974) . -S.H. is a 15 mo. old girl of healthy parents who clinically resembles a pituitary dwarf. Length 60 em (corresp. to age 3 mo.), weight 5.5 kg (-3 mo .), bone age 11 mo. With 5 mo ., basal hGi was 36.4 ng/ml, after arginine max. 46.6 ng/ml. Blood glucose dropped to 26 mg% under arginine. With 10 mo. basal hGi was 58.2 and 65.5 ng/ ml, resp •. Basal SH-levels were 1;99 and 2.03 u/ml (normal mean for age 0 .41 ujml). Stimulation with hGi caused no further rise .-Biological inactivit;y of the hormones measured seems i mprobable , because SH-activit;y was determined biologically and the high SHlevels presumably are the result of the elevated hGi-secretion. Two other patients who clinically exhibited delayed growth and adolescence showed normal basal hGi-levels but significantly increased spontaneous hGi-secretion by night and, in addition, high plasma-SH. Conclusion. In the first case, a pseudo-hypopituitary dwarf with high plasma-hGi and -SH, absolute peripheral resistance against SH seems to be the most plausible explanation. In the 2 other cases, a certain degree of non-responsiveness to SH may playa r61e. The supply of human pituitary growth hormone (hGH) available has been limited by the number of donors . Recently, methionyl-hGH (Genentech) has been synthesized by recombinant DNA techniques. We have compared synthetic methionyl-hGH with pituitary hGH in twelve normal adult male volunteers . Each patient was given 4 daily do ses of 16 U of each hGH with a 10 day period between hGH preparations . Somatomedin-C (SH-C) by RIA was determined daily. Glucose tolerance tests were done prior to the first and after the fourth injection. The SH-C by RIA increased from a baseline of 1 .04 ± 0.07 U/ml to 2 .95 + 0 .20 U/ml with methionyl-hGH and from 1.11 + 0 .06 U/ml to 3.08 + 0.19 U/ml with pituitary hGH. The GTT glucose ares increased fro; 348 + 16 mg%-hr to 475 + 30 mg%-hr and the insulin area increased from-I33 + 19 uU/ml-hr to 403 + 55 uU/ml-hr with methionyl-hGH . The glucose ares increased fro; 333 ± 14 mg%-hr to 435 ± 25 mg%-hr and the insulin area increased from 110 ± 12 uU/mlhr to 324 + 49 uU/ml-hr with pituitary hGH. The equal somatomedin responses are evidence that the synthetic methionyl hGH has full biological activity. The equal changes in glucose metabolism demonstrate that insulin resistence is linked to monocomponent synthetic hGH as well as pituitary hGH. These studies open the way for explorations of uses of methionyl-hGH in human disease states and developmental disorders.
